Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:58:20.509Z.
Calculation as of: 2026-10-06T19:58:20.509Z.
Quote observation: 2026-10-06T19:55:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 444c4789ee5bc9aeb41ce43a5a9ac385aa2bf00f4834dff778c1621e598ef681
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$180.47M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$172.42M
EBITDA Yield
0.46%
TTM Avg
9.63%
3Y Avg
6.71%
5Y Avg
7.90%
Market Cap
$174.46M
EBITDA Yield
N/A
TTM Avg
7985.41%
3Y Avg
7985.41%
5Y Avg
7985.41%
Market Cap
$189.11M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oramed Pharmaceuticals Inc. (ORMP) | $179.26M | N/A | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $180.47M | N/A | N/A | N/A | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $179.75M | N/A | N/A | N/A | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $182.60M | N/A | N/A | N/A | N/A |
| ProQR Therapeutics N.V. (PRQR)vs › | $174.29M | N/A | N/A | N/A | N/A |
| Organogenesis Holdings Inc. (ORGO)vs › | $172.42M | 0.46% | 9.63% | 6.71% | 7.90% |
| Yarrow Bioscience Inc (YARW)vs › | $174.46M | N/A | 7985.41% | 7985.41% | 7985.41% |
| Precision BioSciences, Inc. (DTIL)vs › | $171.13M | N/A | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $189.11M | N/A | N/A | N/A | N/A |
| Journey Medical Corporation (DERM)vs › | $169.53M | 0.74% | 0.65% | 2.68% | 2.68% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
